It’s a testing afternoon for investors who placed bets on Translarna, a drug for a rare form of muscular dystrophy. Shares in PTC Therapeutics, a small biotech group which is developing the medicine, ...
SOUTH PLAINFIELD, N.J., April 14, 2021-- PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new no-charge, patient-initiated testing program in the United States for individuals who have ...
THE coumarin anticoagulants depress the synthesis of four clotting factors: prothrombin; proconvertin (factor VII); Stuart factor (factor X); and plasma thromboplastin component, or PTC (factor IX).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results